Efficacy and Safety of Monthly 150 Mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2011 Oct 22

PMID 22016595

Citations 11

Authors

Young Ho Lee

Gwan Gyu Song

Affiliations

Soon will be listed here.

Abstract

Background/aims: The aim of this study was to assess the efficacy and safety of monthly oral 150 mg ibandronate in women with postmenopausal osteoporosis (PMO).

Methods: A systematic review and meta-analysis were performed to determine treatment efficacy and safety outcomes between monthly oral 150 mg ibandronate and weekly 70 mg alendronate, daily 2.5 mg ibandronate, and a placebo.

Results: Eight randomized controlled trials were included in this systematic review and meta-analysis. Once-monthly 150 mg ibandronate therapy was clinically comparable to weekly 70 mg alendronate, showing increased bone mineral density (BMD) in both the lumbar spine and total hip. Pooled data from two cross-over trials showed that significantly more women with PMO preferred once-monthly ibandronate therapy to once-weekly alendronate therapy (relative risk [RR], 2.422; 95% confidence interval [CI], 2.111 to 2.825; p < 1 × 10(-8)) and found the monthly ibandronate regimen more convenient than the weekly alendronate regimen (RR, 3.096; 95% CI, 2.622 to 3.622; p < 1 × 10(-8)). Monthly 150 mg ibandronate therapy resulted in a significantly higher change in BMD of the lumbar spine than with the placebo. A once monthly 150 mg regimen produced greater increases in lumbar spine, total hip, femoral neck, and trochanter BMD than daily treatment, with a similar incidence of adverse events between the groups.

Conclusions: Once monthly 150 mg ibandronate therapy was clinically comparable to weekly 70 mg alendronate, and patients strongly preferred the convenience of monthly ibandronate over weekly alendronate. Monthly 150 mg ibandronate was superior to, and as well tolerated as, the daily treatment.

Citing Articles

Effect of Lumbar Spinal Stenosis on Treatment of Osteoporosis: Comparison of Three Oral Bisphosphonate Therapies.

Park H, Kim K, Ryu J, Kim G, Jung H, Jung Y J Clin Med. 2023; 12(5).

PMID: 36902814 PMC: 10004629. DOI: 10.3390/jcm12052027.

Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial.

Kim J, Kim K, Lim S, Kang M, Baek K, Min Y BMC Endocr Disord. 2022; 22(1):99.

PMID: 35410197 PMC: 9004203. DOI: 10.1186/s12902-022-01010-w.

Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.

Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I Arch Osteoporos. 2017; 12(1):58.

PMID: 28643265 PMC: 5486684. DOI: 10.1007/s11657-017-0351-2.

Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: A meta-analysis.

Yao L, Wang H, Dong W, Liu Z, Mao H Medicine (Baltimore). 2017; 96(3):e5861.

PMID: 28099343 PMC: 5279088. DOI: 10.1097/MD.0000000000005861.

Body Mass Index May Positively Correlate with Bone Mineral Density of Lumbar Vertebra and Femoral Neck in Postmenopausal Females.

Wu S, Du X Med Sci Monit. 2016; 22:145-51.

PMID: 26766815 PMC: 4716713. DOI: 10.12659/msm.895512.

References

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Cooper A, Drake J, Brankin E . Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006; 60(8):896-905. PMC: 1619408. DOI: 10.1111/j.1742-1241.2006.01059.x. View

Yood R, Emani S, Reed J, Lewis B, Charpentier M, Lydick E . Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003; 14(12):965-8. DOI: 10.1007/s00198-003-1502-4. View

Reginster J, Felsenberg D, Cooper C, Stakkestad J, Miller P, Kendler D . A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int. 2005; 17(2):159-66. DOI: 10.1007/s00198-005-1957-6. View

Sebba A, Emkey R, Kohles J, Sambrook P . Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone. 2008; 44(3):423-7. DOI: 10.1016/j.bone.2008.10.052. View

Stakkestad J, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster J . Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol. 2008; 27(8):955-60. DOI: 10.1007/s10067-007-0824-6. View

Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A . Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine. 2007; 75(3):303-10. DOI: 10.1016/j.jbspin.2007.07.011. View

McClung M, Bolognese M, Sedarati F, Recker R, Miller P . Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. Bone. 2008; 44(3):418-22. DOI: 10.1016/j.bone.2008.09.011. View

10.

Reginster J, Adami S, Lakatos P, Greenwald M, Stepan J, Silverman S . Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2005; 65(5):654-61. PMC: 1798147. DOI: 10.1136/ard.2005.044958. View

11.

Miller P, McClung M, Macovei L, Stakkestad J, Luckey M, Bonvoisin B . Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005; 20(8):1315-22. DOI: 10.1359/JBMR.050313. View

12.

Rossini M, Viapiana O, Gatti D, Adami S . Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther. 2009; 31(7):1497-510. DOI: 10.1016/j.clinthera.2009.07.018. View

13.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

14.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

15.

Lewiecki E, Keaveny T, Kopperdahl D, Genant H, Engelke K, Fuerst T . Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2008; 94(1):171-80. DOI: 10.1210/jc.2008-1807. View

16.

Davey Smith G, Egger M . Meta-analyses of randomised controlled trials. Lancet. 1997; 350(9085):1182. DOI: 10.1016/s0140-6736(05)63833-0. View

17.

Kendler D, Kung A, Fuleihan G, Gonzalez Gonzalez J, Gaines K, Verbruggen N . Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004; 48(3):243-51. DOI: 10.1016/j.maturitas.2003.12.012. View

18.

Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V . Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005; 21(12):1895-903. DOI: 10.1185/030079905X74862. View

19.

Miller P, Epstein S, Sedarati F, Reginster J . Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin. 2007; 24(1):207-13. DOI: 10.1185/030079908x253889. View

20.

Emkey R, Delmas P, Bolognese M, Borges J, Cosman F, Ragi-Eis S . Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther. 2009; 31(4):751-61. DOI: 10.1016/j.clinthera.2009.04.018. View